Menu Search

Company Announcements

Latest announcements

Date and timeCompanyHeadlineSource
UGRO: urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 Player Auction Set for June 1, 2026 @ 5:00 AM EDT (2:30 PM Colombo Time)GlobeNewswire
iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect LingoPR Newswire
CPKC to maintain rail operations across Canada during IBEW strikeCanada Newswire
CPKC to maintain rail operations across Canada during IBEW strikePR Newswire
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in ChinaBusiness Wire
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary SessionPR Newswire
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug DevelopmentBusiness Wire
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limitedPR Newswire
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigmPR Newswire
KALDVIK AS (KLDVK): Q1 2026 Quarterly UpdateGlobeNewswire
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancerPR Newswire
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal CancerBusiness Wire
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual MeetingPR Newswire
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung CancerGlobeNewswire
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanomaGlobeNewswire
EQS-NVR: Adtran Holdings, Inc.: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionEQS Newswire
Nokia Corporation - Managers' transactions (Hanrahan)GlobeNewswire
RNS announcements are delayed by up to an hour.
...